Literature DB >> 22369748

The neutralization sensitivity of viruses representing human immunodeficiency virus type 1 variants of diverse subtypes from early in infection is dependent on producer cell, as well as characteristics of the specific antibody and envelope variant.

Nicholas M Provine1, Valerie Cortez, Vrasha Chohan, Julie Overbaugh.   

Abstract

Neutralization properties of human immunodeficiency virus (HIV-1) are often defined using pseudoviruses grown in transformed cells, which are not biologically relevant HIV-1 producer cells. Little information exists on how these viruses compare to viruses produced in primary lymphocytes, particularly for globally relevant HIV-1 strains. Therefore, replication-competent chimeras encoding envelope variants from the dominant HIV-1 subtypes (A, C, and D) obtained early after infection were generated and the neutralization properties explored. Pseudoviruses generated in 293T cells were the most sensitive to antibody neutralization. Replicating viruses generated in primary lymphocytes were most resistant to neutralization by plasma antibodies and most monoclonal antibodies (b12, 4E10, 2F5, VRC01). These differences were not associated with differences in envelope content. Surprisingly, the virus source did not impact neutralization sensitivity of most viruses to PG9. These findings suggest that producer cell type has a major effect on neutralization sensitivity, but in an antibody dependent manner. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22369748      PMCID: PMC3321740          DOI: 10.1016/j.virol.2012.02.001

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  40 in total

1.  HIV vaccine design and the neutralizing antibody problem.

Authors:  Dennis R Burton; Ronald C Desrosiers; Robert W Doms; Wayne C Koff; Peter D Kwong; John P Moore; Gary J Nabel; Joseph Sodroski; Ian A Wilson; Richard T Wyatt
Journal:  Nat Immunol       Date:  2004-03       Impact factor: 25.606

2.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

Authors:  F L Graham; J Smiley; W C Russell; R Nairn
Journal:  J Gen Virol       Date:  1977-07       Impact factor: 3.891

3.  HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus.

Authors:  E Michelle Long; Stephanie M J Rainwater; Ludo Lavreys; Kishorchandra Mandaliya; Julie Overbaugh
Journal:  AIDS Res Hum Retroviruses       Date:  2002-05-20       Impact factor: 2.205

4.  Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya.

Authors:  J R Neilson; G C John; J K Carr; P Lewis; J K Kreiss; S Jackson; R W Nduati; D Mbori-Ngacha; D D Panteleeff; S Bodrug; C Giachetti; M A Bott; B A Richardson; J Bwayo; J Ndinya-Achola; J Overbaugh
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells.

Authors:  John R Mascola; Mark K Louder; Christine Winter; Ranjani Prabhakara; Stephen C De Rosa; Daniel C Douek; Brenna J Hill; Dana Gabuzda; Mario Roederer
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

6.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

7.  Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.

Authors:  L S Sawyer; M T Wrin; L Crawford-Miksza; B Potts; Y Wu; P A Weber; R D Alfonso; C V Hanson
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.

Authors:  T Muster; F Steindl; M Purtscher; A Trkola; A Klima; G Himmler; F Rüker; H Katinger
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

9.  Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women.

Authors:  Ludo Lavreys; Jared M Baeten; Joan K Kreiss; Barbra A Richardson; Bhavna H Chohan; Wisal Hassan; Dana D Panteleeff; Kishorchandra Mandaliya; Jeckoniah O Ndinya-Achola; Julie Overbaugh
Journal:  J Infect Dis       Date:  2004-01-09       Impact factor: 5.226

10.  Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Authors:  Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton
Journal:  Science       Date:  2009-09-03       Impact factor: 47.728

View more
  20 in total

1.  Single genome amplification and standard bulk PCR yield HIV-1 envelope products with similar genotypic and phenotypic characteristics.

Authors:  Behzad Etemad; Melissa Ghulam-Smith; Oscar Gonzalez; Laura F White; Manish Sagar
Journal:  J Virol Methods       Date:  2015-02-11       Impact factor: 2.014

Review 2.  Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies: model parameter considerations and consequences.

Authors:  Gregory Q Del Prete; Jeffrey D Lifson; Brandon F Keele
Journal:  Curr Opin HIV AIDS       Date:  2016-11       Impact factor: 4.283

3.  Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env.

Authors:  Amelia Escolano; Harry B Gristick; Rajeev Gautam; Andrew T DeLaitsch; Morgan E Abernathy; Zhi Yang; Haoqing Wang; Magnus A G Hoffmann; Yoshiaki Nishimura; Zijun Wang; Nicholas Koranda; Leesa M Kakutani; Han Gao; Priyanthi N P Gnanapragasam; Henna Raina; Ana Gazumyan; Melissa Cipolla; Thiago Y Oliveira; Victor Ramos; Darrell J Irvine; Murillo Silva; Anthony P West; Jennifer R Keeffe; Christopher O Barnes; Michael S Seaman; Michel C Nussenzweig; Malcolm A Martin; Pamela J Bjorkman
Journal:  Sci Transl Med       Date:  2021-11-24       Impact factor: 19.319

4.  Antibody-dependent cell-mediated virus inhibition antibody activity does not correlate with risk of HIV-1 superinfection.

Authors:  Donald N Forthal; Gary Landucci; Bhavna Chohan; Barbra A Richardson; R Scott McClelland; Walter Jaoko; Catherine Blish; Julie Overbaugh
Journal:  J Acquir Immune Defic Syndr       Date:  2013-05-01       Impact factor: 3.731

5.  Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides.

Authors:  Krystal Teasley Hamorsky; Tiffany W Grooms-Williams; Adam S Husk; Lauren J Bennett; Kenneth E Palmer; Nobuyuki Matoba
Journal:  Antimicrob Agents Chemother       Date:  2013-02-12       Impact factor: 5.191

6.  Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock.

Authors:  Michael Lopker; Juliet Easlick; Sarah Sterrett; Julie M Decker; Hannah Barbian; Gerald Learn; Brandon F Keele; James E Robinson; Hui Li; Beatrice H Hahn; George M Shaw; Katharine J Bar
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103

7.  Characterization of HIV-1 envelopes in acutely and chronically infected injection drug users.

Authors:  Behzad Etemad; Oscar A Gonzalez; Laura White; Oliver Laeyendecker; Gregory D Kirk; Shruti Mehta; Manish Sagar
Journal:  Retrovirology       Date:  2014-11-28       Impact factor: 4.602

8.  Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones.

Authors:  Joshua Baalwa; Shuyi Wang; Nicholas F Parrish; Julie M Decker; Brandon F Keele; Gerald H Learn; Ling Yue; Eugene Ruzagira; Deogratius Ssemwanga; Anatoli Kamali; Pauli N Amornkul; Matt A Price; John C Kappes; Etienne Karita; Pontiano Kaleebu; Eduard Sanders; Jill Gilmour; Susan Allen; Eric Hunter; David C Montefiori; Barton F Haynes; Emmanuel Cormier; Beatrice H Hahn; George M Shaw
Journal:  Virology       Date:  2012-11-01       Impact factor: 3.616

Review 9.  HIV vaccinology: 2021 update.

Authors:  Jeong Hyun Lee; Shane Crotty
Journal:  Semin Immunol       Date:  2021-07-14       Impact factor: 10.671

10.  HIV-1 envelope replication and α4β7 utilization among newly infected subjects and their corresponding heterosexual partners.

Authors:  Victor Pena-Cruz; Behzad Etemad; Nikolaos Chatziandreou; Phyu Hninn Nyein; Shannon Stock; Steven J Reynolds; Oliver Laeyendecker; Ronald H Gray; David Serwadda; Sandra J Lee; Thomas C Quinn; Manish Sagar
Journal:  Retrovirology       Date:  2013-12-26       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.